SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Sotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Lonza’s centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO Biotech owned by Polish PPF Group.
Under the terms of the agreement, SOTIO will gain access to Synaffixs ADC technologies, GlycoConnect, HydraSpace and toxSYN linker-payloads, in an initial ADC program with the option to expand research and commercial licenses into two additional programmess at a later date.
According to the contract, Synaffix will be eligible to receive up to US$740m in payments spanning signature, target nomination and milestone payments plus additional royalties on commercial sales. SOTIO will be responsible for the research, development, and commercialisation of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies
Biocytogen Co Ltd
